Semaglutide and Its Siblings: Are We Trying to Eat the Cake and Have It Too? Or are we teaching the body to forget hunger while the world that made it hungry stays the same?

Semaglutide and its siblings—tirzepatide, retatrutide and newer oral formulations—are transforming the treatment of obesity and metabolic disease. Their success is real. But does extraordinary efficacy risk making us ask too few questions?The SELECT trial demonstrated a 20% reduction in major cardiovascular events in people with overweight or obesity, established cardiovascular disease and no diabetes. FLOW demonstrated substantial kidney protection in people with type 2 diabetes and chronic kidney disease. These are important clinical advances.Yet we should be careful about what we infer from them. Do benefits appearing before substantial measured weight loss necessarily imply a direct vascular effect? Not necessarily. Appetite and energy intake change from the first dose; weight loss is continuous, and metabolic and inflammatory changes may begin before a large change appears on the scales. Perhaps Occam’s razor applies: weight loss, beginning almost immediately, may explain more of the benefit than we assume.Then comes the harder question of persistence. Many real-world patients discontinue within a year. If benefits depend on continued pharmacological suppression of appetite, what happens when treatment stops? The biological drive toward weight regain may re-emerge.Rapid weight reduction can also reduce lean body mass along with fat, raising concern about muscle loss and sarcopenia in vulnerable individuals. This does not negate the benefits of weight loss; it reminds us that what is lost may matter as much as how much is lost.There are also questions beyond body composition. Appetite does not operate in isolation; neural pathways regulating food intake intersect with reward and motivation. GLP-1-based therapies are being investigated for effects on alcohol use, nicotine dependence and other reward-driven behaviours. These possibilities may prove therapeutically valuable. But what are the consequences of suppressing these signals for decades? At present, we do not know. That is not an argument against treatment; it is an argument against premature certainty.The deeper issue is not whether these drugs work. They do.It is whether suppressing hunger is the same as correcting the conditions that made us hungry.These drugs can suppress hunger and reduce energy intake; they cannot, by themselves, redesign the food environment, reverse sedentary living, relieve chronic stress or repair disrupted sleep. When treatment stops, pharmacological suppression of appetite stops too, and in many patients the biological drive toward weight regain re-emerges.Thiruvalluvar, writing on medicine some two thousand years before the first GLP-1 molecule, put the matter more economically than any trial report can:“Once digested, eat with moderation; that prolongs the life of one embodied.” — Kural 943Two thousand years on, we have found a molecule that can pharmacologically quiet the appetite that the Kural asked us to govern ourselves.Whether that counts as an answer—or merely an ingenious way of postponing the same old question—is something the data have not yet settled.Perhaps the real question is not whether we can make ourselves less hungry.It is whether we should be satisfied with treating hunger while leaving the obesogenic world unchanged.Read the full article: Semaglutide and Its Siblings: Are We Trying to Eat the Cake and Have It Too?